Biohaven Ltd. has finished enrolling the target of approximately 150 participants in its Phase 2 proof‑of‑concept study of taldefgrobep alfa, a myostatin‑activin pathway inhibitor designed to reduce body weight and fat mass while preserving lean muscle in adults with overweight or obesity.
The study, which began in early 2025, will now enter a 24‑week double‑blind, placebo‑controlled treatment period followed by a 24‑week open‑label extension. Top‑line data are expected in the second half of 2026, marking a critical step toward the study’s primary endpoint and the first large‑scale assessment of taldefgrobep alfa’s efficacy and safety.
Taldefgrobep alfa demonstrated favorable body‑composition effects in Phase 1 trials, with reductions in fat mass and increases in lean muscle mass observed in more than 700 participants and a favorable safety profile. The Phase 2 study will test whether these benefits translate to a diverse, real‑world population and whether the drug can achieve clinically meaningful weight loss without compromising muscle mass.
The obesity market is dominated by GLP‑1 agonists, but many patients and clinicians are concerned about muscle loss associated with weight‑loss therapies. By targeting the myostatin‑activin pathway, taldefgrobep alfa could offer “high‑quality weight loss” that preserves muscle, potentially differentiating it from existing agents and addressing an unmet need in the market.
"We are at a watershed moment in the treatment of obesity, brought on by the introduction of highly effective therapies like the GLP‑1 agonists. To realize optimal long‑term health outcomes, however, we will need to look beyond maximizing weight reduction and remain vigilant around the importance of muscle mass in overall health and wellness," said Frank Greenway, M.D., Professor and Chief Medical Officer of the Clinical Trials Unit at Pennington Biomedical Research Center. "We are excited to evaluate taldefgrobep, as both a once‑weekly and once‑monthly dosing regimen, in an obese patient population," added Peter Ackerman, M.D., Senior Vice President of Clinical Development at Biohaven. "We believe taldefgrobep could represent an important new agent, as monotherapy and in combination with the current standard of care, that can help optimize high‑quality weight loss in people living with obesity."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.